Amarin Corporation PLC Stock News

Amarin Corporation plc (AMRN) CEO Karim Mikhail on Cowen 42nd Annual Health Care Conference (Transcript)

In the latest trading session, 0.62 million Amarin Corporation plc (NASDAQ:AMRN) shares changed hands as the company’s beta touched 2.09. With the company’s most recent per share price at $3.23 changing hands around $0.04 or 1.35% at last look, the market valuation stands at $1.23B. AMRN’s current price is a discount, trading about -126.01% off … Is Amarin Corporation plc (NASDAQ: AMRN) Stock Set To Rise More? Read More »

Amarin's (AMRN) Vascepa sales decline amid rising generic competition and COVID-19 related disruptions during the fourth quarter. The company's stock falls on Mar 1, following the earnings release.

Amarin's (AMRN) Vascepa sales decline amid rising generic competition and COVID-19 related disruptions during the fourth quarter. The company's stock falls on Mar 1, following the earnings release.

AMRN earnings call for the period ending December 31, 2021.

AMRN earnings call for the period ending December 31, 2021.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine, Inc. (NASDAQ: EDIT) sai

Amarin (AMRN) rose pre-market after its Q4 results beat analysts'' estimates.Full year 2021 Total net revenue decreased 5.03% Y/Y to $583.19M. Net product revenue fell 4% Y/Y…

Amarin Corp plc''s (NASDAQ: AMRN ) Q4 FY21 sales decreased 13.6% Y/Y to $144.49 million , beating the consensus of $141.75 million. The decline was driven primarily by the volume of Vascepa sales adversely impacted by the generic icosapent ethyl market entrants and the ongoing challenges of the COVID-19 pandemic. The cost of goods sold was $30.63 million, compared to $34.76 million. Amarin''s overall gross … Full story available on Benzinga.com

Amarin press release (AMRN): Q4 Non-GAAP EPS of $0.06 beats by $0.09.Revenue of $144.49M (-13.6% Y/Y) beats by $2.32M.As of December 31, 2021, Amarin reported aggregate cash…

Go-to-Market Strategy in U.S. to Optimize Provider Engagement and Drive Demand for VASCEPA®

Amarin (NASDAQ:AMRN) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open.The consensus EPS Estimate is -$0.03 (vs $0.04 in Q420) and the consensus…

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, is